CP-GEP is a non-invasive predictive model for cutaneous melanoma patients. Credit: Arif biswas/Shutterstock.

SkylineDx, a biotech company, has announced new findings from the MERLIN_001 clinical trial of melanoma genomic assay, Merlin test, in the US.

The trial has validated the Clinical-Pathologic and Gene Expression Profile (CP-GEP) test for the identification of sentinel lymph node biopsy (SLNB) status in high-risk cutaneous melanoma patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This non-invasive model combines clinicopathologic variables with gene expression profiling to improve the accuracy of SLNB predictions.

Carried out across nine US academic sites, the trial was led by Dr Vernon Sondak of Moffitt Cancer Centre, Dr T. Hieken from the Mayo Clinic and Dr M. Egger of UofL Health Brown Cancer Centre.

Sondak, one of the three principal investigators of the MERLIN_001 trial said: “This landmark trial will allow us to have more informed conversations with our patients about their surgical treatment options. These results provide critical insights for clinicians, allowing us to move toward more precise and individualised care.”

See Also:

The Merlin test integrates factors such as age and Breslow thickness with an eight-gene expression profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Validated in a population with an SLN positivity rate of more than 17%, the test classified 37% of the 1,686 melanoma patients as low risk, with only 7.1% of these patients having a positive SLN.

This indicates a negative predictive value of 92.9%. Conversely, 23.8% of high-risk patients reported positive SLNs, demonstrating the test’s stratification capabilities.

The CP-GEP model, developed by Mayo Clinic and SkylineDx, has undergone clinical validation in multiple studies.

The Merlin test is now available in the US and Europe, with SkylineDx partnering with diagnostic service providers such as Tempus in the US for the Tempus Merlin test.